Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
Trial details
- Registry ID
- NCT04971109
- Drugs studied
- TPOXX
TrialRedline tracks 4 clinical trials sponsored by SIGA Technologies: 2 Phase 3, 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 DaysNCT04971109 | TPOXX | Completed | 2023-05-12Actual |
| A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound TecovirimatNCT02474589 | tecovirimat | Completed | 2016-08-24Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOSNCT04957485 | Smallpox and Mpox Vaccine, Tecovirimat | Active not recruiting | 2027-01-01Estimated |
| Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246NCT00907803 | ST-246 400 mg, ST-246 600 mg | Completed | 2010-01Actual |
Names as written in the registry records.
NCT04957485 · SIGA Technologies
Before: 1 Jan 2026. After: 1 Jan 2027.